HAVCR2 and metastatic neoplasm: A same trend was also observed in patients treated with targeted agents: TIM-3 expression in the metastatic tumors significantly increased the PA values of PFS (from 73.5 to 79.1%, P = 0.006) and OS (from 84.2 to 87.3%, P = 0.009) models (Table 6).